Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
NCT07453875Phase 1Not yet recruiting
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in gastric cancer (GC) and colorectal cancer (CRC). Primary endpoint: Incidence of treatment-emergent adverse events at 2 years. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07453875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453875.